ALNY Alnylam Pharmaceuticals

$264.30 -1.10%

Updated 16 d ago

Healthcare · Pharmaceutical Preparations

Alnylam Pharmaceuticals (ALNY) is a healthcare company in the Pharmaceutical Preparations industry, with a market capitalization of $35.4 billion. Shares last traded at $264.30, 46.6% below their 52-week high. Over the past year the stock is down 40.8%. ALNY trades at a price-to-earnings ratio of 43.77, above the Pharmaceutical Preparations median of 17.31. Net profit margin is 21.8%, above the peer median of -8.9%. Revenue grew 65.2% year over year.

Market Cap

$35.4B

Shares Out

133.8M

EPS (TTM)

$-0.18

P/E Ratio

43.77

P/S Ratio

9.52

P/B Ratio

26.12

Dividend / Share

—

Dividend Yield

—

52-Week High

$495.30

52-Week Low

$197.95

Volume

116,048

Avg Vol (3m)

126,123.952

Performance

+11.78%

+14.92%

-7.60%

-17.05%

YTD

-33.93%

-40.77%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

61.26

SMA (50)

$259.31

SMA (200)

$323.73

Price vs SMA50

+1.92%

Price vs SMA200

-18.36%

ATR (14)

$11.88

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue

$3.7B

Net Income

$808M

Gross Margin

—

Operating Margin

13.5%

Net Margin

21.8%

Return on Equity

59.7%

Return on Assets

14.5%

Current Ratio

3.05

Debt / Equity

0.50

Revenue Growth (YoY)

+65.2%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

Period	EPS (diluted)	Reported
Q2 2026	$2.71	2026-07-30
FY 2025	$2.33	2026-02-12
FY 2025	$1.51	2026-02-12
Q2 2026	$-0.70	2026-07-30
FY 2025	$-0.14	2026-02-12
FY 2025	$-2.18	2026-02-12

Full earnings history →

Pharmaceutical Preparations peers

ALNY vs 14 industry peers (Pharmaceutical Preparations), by market cap. Updated 16 d ago

P/E vs peers

43.77 / 17.31 med

+153% premium

P/S vs peers

9.52 / 11.11 med

-14% discount

Net margin vs peers

21.8% / -8.9% med

above median

1–14 of 14


LLY	Lilly (Eli)	$1.09T	40.86	13.70	33.5%	-0.02%
JNJ	Johnson & Johnson	$670.6B	31.88	6.85	21.5%	+1.04%
ONC	Beone Medicines Ltd.	$535.9B	817.25	87.43	10.7%	+0.23%
ABBV	AbbVie	$459.8B	72.87	7.14	9.8%	-0.57%
MRK	Merck	$375.8B	118.44	5.65	4.8%	+0.44%
ABT	Abbott Laboratories	$189.5B	30.20	4.20	13.9%	-1.50%
PFE	Pfizer	$164.2B	37.91	2.58	6.8%	-0.76%
VRTX	Vertex Pharmaceuticals	$141.5B	32.11	11.24	35.0%	+0.24%
BMY	Bristol Myers Squibb	$139.1B	14.98	2.83	18.9%	+0.62%
REGN	Regeneron Pharmaceuticals	$87.2B	20.15	5.61	27.9%	-1.02%
TEVA	Teva Pharmaceutical Industries Ltd	$42.6B	60.41	2.46	4.1%	-2.32%
ALNY	Alnylam Pharmaceuticals	$35.4B	43.77	9.52	21.8%	-1.10%
ZTS	Zoetis	$31.5B	12.05	3.31	27.5%	+0.16%
RPRX	Royalty Pharma Plc	$28.2B	34.56	11.11	32.1%	+1.24%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.